GCT to Manage Bioequivalence Study in Healthy Volunteers

Calcium channel blockers are medications used to lower blood pressure.

Last week, GCT has been selected to conduct a bioequivalence clinical trial in a calcium channel blocker, Manidipine. The randomized, two treatment, two sequence, two way cross over, bioequivalence study of Manidipine Dihydrochloride tablets will be performed in Ukraine with participation of 30 healthy volunteers.

GCT will manage the full-service study support including medical writing, clinical and medical monitoring, regulatory, project management, site and vendor management, data management and biostatistics.

“We are thrilled to enhance our cardiovascular trials portfolio in Ukraine and to build strong partnership with our new client,” – said Dr. Jeffrey Apter, GCT President.

GCT has deep experience in the management and execution of BE / BA / PK clinical trials, in Ukraine and globally.

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.


GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login



© 2001—2021 Global Clinical Trials, LLC

All rights reserved.